ey0021.2-1 | New Therapies | ESPEYB21
P Thornton
, D De Leon
, S Empting
, D Zangen
, D Kendall
, S Sune Birch
, E Boge
, J Ivkovic
, I Banerjee
Brief Summary: This open-label, randomised phase 3 trial investigated the efficacy and safety of subcutaneous infusions of Dasiglucagon1, a glucagon analogue, as an add-on to standard of care (SoC) treatment in infants and children with congenital hyperinsulinism (CHI).Patients had documented CHI aged 0.6 to 10.9y, who had ≥3 episodes of hypoglycemia/week, defined as self-measured plasma glucose (SMPG) <3.9 mmol/L. Part 1 (weeks 1-4)...